Reuters: Regulatory News: U.S. FDA approves Theravance's lung drug for wider use

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

U.S. FDA approves Theravance's lung drug for wider use Jun 21st 2013, 22:11 June 21 | Fri Jun 21, 2013 6:11pm EDT June 21 (Reuters) - The U.S. Food and Drug Administration approved Theravance Inc's antibiotic lung drug to treat a type of bacterial pneumonia affecting hospitalized patients, particularly those on ventilators. The drug, Vibativ, will reach the market in the third quarter of 2013 for its expanded use. The drug is already approved in the United States and Canada to treat bacterial skin infections.. The disease, also known as nosocomial pneumonia, is a serious lung infection as patients, particularly those on ventilators, often cannot fight the infection. The regulator said on Friday that Vibativ will be prescribed only when alternative treatments are not suitable and the expanded use is to treat only bacterial pneumonia due to staphylococcus aureus. () Vibativ is already approved in Europe for the treatment of adults with nosocomial pneumonia. Theravance's shares were up about 2 percent at $38.25 in after-market trading. The shares closed up 10 percent at $37.5 on the Nasdaq following a Daily Mail's market report that GlaxoSmithKline is lining up a $55 per share bid for Theravance.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions